Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2155526 | Pathology - Research and Practice | 2014 | 8 Pages |
Abstract
Diabetes increases cancer risk, which may be modulated by careful choice of treatment. Experimental reports showed efficacy of glitazones in various in vitro and in vivo models of carcinogenesis, but procarcinogenic effects in some models were reported too, and, similarly, data on cancer incidence in glitazone users are inconsistent. This review summarizes oncostatic effects of glitazones in preclinical and clinical studies and brings a brief summary of their impact on cancer risk in diabetic patients, with a focus on the association between pioglitazone use and bladder cancer.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Bianka Bojková, Peter Orendáš, Peter Kubatka, Martin Péč, Monika Kassayová, Terézia Kisková, Karol Kajo,